Elpek GO. Mixed neuroendocrine–nonneuroendocrine neoplasms of the gastrointestinal system: An update. World J Gastroenterol 2022; 28(8): 794-810 [PMID: 35317101 DOI: 10.3748/wjg.v28.i8.794]
Corresponding Author of This Article
Gulsum Ozlem Elpek, MD, Professor, Pathology , Akdeniz University Medical School, Dumlupınar bulvarı, Antalya 07070, Turkey. elpek@akdeniz.edu.tr
Research Domain of This Article
Pathology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 28, 2022; 28(8): 794-810 Published online Feb 28, 2022. doi: 10.3748/wjg.v28.i8.794
Table 1 Discrimination among mixed neuroendocrine-nonneuroendocrine neoplasms, neuroendocrine tumors, and carcinomas according to pathological parameters
Table 3 Summary of the therapy protocols applied to localized mixed neuroendocrine-nonneuroendocrine neoplasms
Surgery
Complete resection is possible
Complete resection is not possible
MiNEN grade
High
Intermediate
Low
High
Intermediate
Low
Chemotherapy
PDNEC-like
ADC-like
NR
PDNEC-like
ADC- like
NET-like
Table 4 Summary of the therapy protocols applied to metastatic mixed neuroendocrine-nonneuroendocrine neoplasms
Metastatic component
Defined
Not defined
One component
Two components
Chemotherapy target
The metastatic component
The most aggressive component
The most aggressive component in the primary tumor
Citation: Elpek GO. Mixed neuroendocrine–nonneuroendocrine neoplasms of the gastrointestinal system: An update. World J Gastroenterol 2022; 28(8): 794-810